Etelix Closes Month of May With $1,201,102 in Revenue
NEW YORK, NY, June 26, 2018 (GLOBE NEWSWIRE) -- Metrospaces, Inc. (OTC: MSPC) announces that Etelix continues monthly revenue growth at above forecast.
Mr. Silva stated: “January to May revenue budgeted forecast was $3,800,293. However, May revenue of $1,201,102 now brings total January to May 2018 revenue to $4,493,570. This is an increase of 18% over forecast and sets the company revenue at a $14 million annual run rate, as opposed to $7.6 million in revenue for 2017. It’s been an amazing year, and the wonderful thing is that most of our recently executed interconnection agreements are not yet at full capacity. Having achieved this amazing revenue growth, while still being cash flow positive on an EBITDA basis is even more notable. This continued above-forecast growth is setting the company up for some very exciting new prospects such as the continued hiring of world-class talent as well as new potential acquisitions the company is now considering. Being able to handle this sort of revenue and operating profit growth is giving the company confidence to approach more and more companies for potential acquisitions. Although Etelix is still held as a private company, our internal valuation methods have this already be an acquisition that has surpassed all our expectations.”
About Etelix.com USA, LLC
Etelix.com USA (http://www.etelix.com/) is a Miami-based, FCC-licensed voice, SMS and data/hosting operator. The company’s main products and services are international voice wholesale, data and hosting services as well as residential and commercial triple-play provider. The company was founded in 2007 and has been profitable since inception.
About Metrospaces
Metrospaces www.metrospaces.net is a publicly traded real estate investment and Development Company which acquires land, designs, builds, and develops then resells condominiums and Luxury High-End Hotels, principally in urban areas of Latin America. The company’s current projects are located in Buenos Aires, Argentina, and Miami, USA. It is operated by an elite group of real estate and investment professionals and entrepreneurs located in New York City, Miami and Buenos Aires. Company shareholders have extensive careers in real estate and business financing worldwide and have funded projects both in the America’s and across Europe valued in excess of US $550Million.
Metrospaces’ majority shareholders have partnered with Investors on Elite properties including The London BLVGARI 5 Star Hotel, and is currently involved in negotiations for the development of several Elite luxury properties in South America.
Among Metrospaces’ partners are Architects, Real Estate Developers, Agents and Attorneys of the highest standing, with extensive experience in the global property market.
Metrospaceswas originally founded by company President Oscar Brito.
Relevant Links:
Safe Harbor Statement:
Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Metrospaces Inc. undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.
CONTACT: Company Contact: Tel: (646) 630-0927 Investor Relations: investors@metrospaces.net
© 2018 GlobeNewswire, Inc. All Rights Reserved.
U.S. FDA Approves Gilead Sciences' (Nasdaq: GILD) Antiviral Veklury (remdesivir) for the Treatment of COVID-19
